WTA’s new SRY test: the short version (and why everyone’s talking)

Right, so the WTA just dropped a pretty big change: they’re asking every player on the women’s tour to take a one-off genetic sex test that looks for the SRY gene, and you need a negative result to be eligible under the new rule. That’s the headline. It matters because it swaps out the hormone-based rules we’d been using for a genetic screen — and that switch has already set off a predictable storm of praise, worry and legal-ethics questions. The WTA’s rollout has been covered by outlets including ESPN and the BBC, and those reports are the basis for everything I’m going to walk you through.

What the policy actually requires

First things first: the test is mandatory and one-time only. Players will provide a sample — cheek swab, blood, or saliva — and labs will check for the presence of the SRY gene. That’s the WTA’s marker for “biological sex” in this policy. The organization says you need a negative result to compete on the tour under the updated eligibility rules, which is a big shift from how they’ve handled things recently. The BBC lays out the sample options and the one-off nature of the test.

Important nuance: testing positive doesn’t mean an automatic ban. The WTA says any positive result will trigger further medical assessment first. And if a player refuses the test, the policy requires them to sign a document acknowledging possible disciplinary action. That mix of mandatory swabs plus a step for follow-up is central to how the WTA is framing the change. The announcement and context were reported by ESPN.

Why this is a big deal: science, fairness and a rules U-turn

The immediate reason this feels seismic is that it changes the yardstick. Up until 2024 the WTA’s framework allowed transgender women to compete if they kept testosterone below a certain level — specifically, 2.5 nmol/L for two continuous years, according to the WTA’s prior policy as reported by the BBC.

Switching from a hormone-based test to a genetic screen is not a tweak. It’s a different philosophy of what “eligibility” means. Hormones are about current physiological state; genes are forever. That’s why people are locked into debate already.

How the testing will work in practice

Samples and logistics

The WTA says samples can be taken via cheek swab, blood draw or saliva. One time. From then on, your genetic marker is in the record — at least for the purposes of eligibility under this policy. The BBC outlines those practical details.

Positive results: not an instant ban

If a test detects the SRY gene, the player isn’t automatically kicked off the tour. Instead, they’ll go through further medical assessment before any final decision. That’s potentially important — it suggests the WTA is aware that biology isn’t always binary and that genetics can be complicated.

That said, the policy also warns of disciplinary consequences if a player refuses testing. So the WTA has tried to make this mandatory while leaving room for case-by-case medical review after a positive result. As BBC reported, that balance between mandatory and discretionary is baked into the text.

Where the criticism is coming from

Human-rights groups and advocacy organizations have already criticized similar mandatory sex/gene-screening rules in other sports, and they’re not alone in raising red flags about this one.

Concerns fall into a few clear buckets:

• Privacy: genetic testing is uniquely personal, and storing or processing genetic data raises obvious privacy and security questions.
• Medical complexity: genetics and sex traits don’t always line up in simple ways. Plenty of medical conditions can complicate a clean SRY positive/negative narrative.
• Discrimination risks: critics say mandatory testing could stigmatize or exclude people in ways that hormone-based rules — while imperfect — tried to mitigate.

Those critiques aren’t invented by commentators on Twitter — they echo long-standing concerns human-rights experts have raised about sex screening in sport, and they were flagged in reporting by ESPN.

WTA’s reply so far

The WTA has framed this as a move to preserve fair competition and said the new standard is being aligned with broader eligibility expectations, including notes about alignment with Olympic standards for Los Angeles 2028. The organization has insisted the policy is based on biological sex, not gender identity, and said it has “no intent to disrespect or question” anyone’s dignity, according to the initial reporting in ESPN.

Timing and the Olympic angle

Timing matters here. The WTA’s announcement is linked in reports to eligibility standards for the 2028 Los Angeles Olympics. That connection raises a lot of pragmatic questions about how the tour wants its rules to line up with international multisport bodies and the games’ selection criteria.

That plausible push to harmonize rules ahead of 2028 helps explain the urgency, but it also widens the debate — because Olympic eligibility touches national federations, anti-doping bodies, and the IOC’s own standards. The rollout therefore isn’t just a WTA matter; it’s part of a larger conversation about eligibility across elite sport, as noted in the initial coverage by ESPN and the BBC.

Immediate practical fallout — what changes on court?

Short answer: you probably won’t see matches decided by this next week. The coverage so far focuses on eligibility and controversy, not match results, player injuries, or transfers related to the rule. The BBC also reports that there are no known transgender women currently playing on the WTA Tour, which frames the current practical impact as limited — at least for now.

But “limited for now” doesn’t mean the policy won’t matter. Changing the rulebook affects future entrants, national federation selections for events like the Olympics, and the climate around inclusion on tour. Those are slow-burn effects that change who gets to play over time.

What we don’t know — and what to watch next

The WTA’s policy is the headline, but there are plenty of unanswered questions that will determine how disruptive this actually is.

• How will genetic data be stored and who will have access? The reporting so far notes the testing requirement but doesn’t detail the data-protection protocols.
• How will the “further medical assessment” after a positive result actually work? Who decides, and on what criteria?
• Will national federations or the IOC push back or try to harmonize a different approach before 2028?
• Could this prompt legal challenges from players or advocacy groups? Coverage mentions criticism from rights groups, but specific legal actions weren’t reported in the initial stories.

For now, the initial coverage sets the framework and the flashpoints. Expect the next phase to be about detail: implementation, appeals, and privacy safeguards.

Why players and fans should pay attention

If you care about who gets to play and the integrity of competition, this is a core policy change. It’s not just a technical tweak; it redefines how the sport answers the question “Who is a woman?” at the elite level.

That matters in at least three ways:

• Future competitors: anything that changes the entry bar alters who comes onto the tour over time.
• Selection for big events: Olympic eligibility linkages mean national teams and selectors are watching closely.
• Culture shift: mandatory genetic testing sends a message about how the tour thinks about sex and gender — and that message affects players’ sense of safety and belonging.

FAQ — the things you actually want answered

Is the test really mandatory?

Yes. The WTA requires the one-off test for all players under the updated eligibility policy. Players who refuse must sign paperwork that acknowledges they could face disciplinary action, per reporting in the BBC.

What exactly does the WTA test for?

They’re testing for the SRY gene. That’s the genetic marker the WTA is using to make decisions about biological sex under this policy, as reported by ESPN.

If someone tests positive, are they banned?

No, a positive result doesn’t automatically mean a ban. The policy states that positive tests will lead to further medical assessment before any eligibility decision is made, according to the BBC.

How does this compare with the old rule on transgender athletes?

Before this change, the WTA’s 2024 framework allowed transgender women to play if their testosterone was kept below 2.5 nmol/L for two continuous years. This new rule shifts the focus from hormones to genetics, which is a fundamental change in approach — as discussed in the BBC coverage.

Are any players immediately affected?

Reports note there are no known transgender women currently playing on the WTA Tour. So the immediate on-court impact appears limited, but the policy does affect future entrants and selection processes for events like the Olympics, per the BBC.

Why are people upset about this?

Critics — including human-rights and advocacy groups — say mandatory genetic testing raises privacy, discrimination and medical-accuracy concerns. Similar policies in other sports have attracted strong pushback, which is why coverage from outlets like ESPN highlights the controversy.

Wrap-up: one thing to remember

This isn’t a small tweak. The WTA has moved from a hormone-based eligibility model to a permanent genetic screen, and that’s going to shape who competes, how national bodies select for major events, and the broader culture around inclusion on the tour. Whether you think it’s the right move or not, it’s going to be a defining policy debate in women’s sport for the next few years.